Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | ONCOLOGY//CELL BIOLOGY//BIOCHEMISTRY & MOLECULAR BIOLOGY | 2934640 |
196 | 3 | LUNG CANCER//NON SMALL CELL LUNG CANCER//THORAC SURG | 53631 |
440 | 2 | GEFITINIB//EGFR//EPIDERMAL GROWTH FACTOR RECEPTOR | 16519 |
11170 | 1 | 4 ANILINOQUINAZOLINE//ANILINOQUINAZOLINE//COMBI MOLECULE | 1030 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | 4 ANILINOQUINAZOLINE | authKW | 493625 | 2% | 73% | 22 |
2 | ANILINOQUINAZOLINE | authKW | 344212 | 1% | 75% | 15 |
3 | COMBI MOLECULE | authKW | 314712 | 1% | 86% | 12 |
4 | CANC DRUG | address | 304167 | 1% | 76% | 13 |
5 | EGFR TK INHIBITORS | authKW | 225304 | 1% | 82% | 9 |
6 | MED ONCOL MEDCANC DRUG | address | 214181 | 1% | 100% | 7 |
7 | QUINAZOLINE | authKW | 190555 | 6% | 9% | 66 |
8 | CANC DRUG MED MED ONCOL | address | 183584 | 1% | 100% | 6 |
9 | TYRPHOSTIN | authKW | 169914 | 3% | 18% | 31 |
10 | MED MED ONCOLCANC DRUG | address | 152986 | 0% | 100% | 5 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Chemistry, Medicinal | 20110 | 41% | 0% | 425 |
2 | Chemistry, Organic | 2201 | 22% | 0% | 224 |
3 | Pharmacology & Pharmacy | 920 | 19% | 0% | 199 |
4 | Oncology | 872 | 17% | 0% | 173 |
5 | Biochemistry & Molecular Biology | 392 | 20% | 0% | 205 |
6 | Chemistry, Multidisciplinary | 96 | 9% | 0% | 96 |
7 | Radiology, Nuclear Medicine & Medical Imaging | 42 | 4% | 0% | 39 |
8 | Biochemical Research Methods | 42 | 3% | 0% | 32 |
9 | Crystallography | 40 | 2% | 0% | 24 |
10 | Computer Science, Interdisciplinary Applications | 30 | 2% | 0% | 22 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | CANC DRUG | 304167 | 1% | 76% | 13 |
2 | MED ONCOL MEDCANC DRUG | 214181 | 1% | 100% | 7 |
3 | CANC DRUG MED MED ONCOL | 183584 | 1% | 100% | 6 |
4 | MED MED ONCOLCANC DRUG | 152986 | 0% | 100% | 5 |
5 | MED ONCOLCANC DRUG | 152986 | 0% | 100% | 5 |
6 | BIOMMUNOTHER Y | 61195 | 0% | 100% | 2 |
7 | CANC DRUG HLTH | 61195 | 0% | 100% | 2 |
8 | CHEM SCI ONCOL IMMUNOINFLAMMATORY | 61195 | 0% | 100% | 2 |
9 | MED ONCOLHLTH GLEN HOSP | 61195 | 0% | 100% | 2 |
10 | MED ONCOLHLTH ROYAL VICTORIA HOSP | 61195 | 0% | 100% | 2 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | JOURNAL OF MEDICINAL CHEMISTRY | 9595 | 8% | 0% | 83 |
2 | ANTI-CANCER DRUG DESIGN | 9537 | 1% | 2% | 14 |
3 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 9327 | 9% | 0% | 89 |
4 | BIOORGANIC & MEDICINAL CHEMISTRY | 7087 | 5% | 0% | 56 |
5 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 3148 | 3% | 0% | 32 |
6 | ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 3121 | 1% | 1% | 11 |
7 | CHEMICAL BIOLOGY & DRUG DESIGN | 2902 | 1% | 1% | 13 |
8 | EXPERT OPINION ON THERAPEUTIC PATENTS | 1603 | 1% | 0% | 11 |
9 | ORGANIC PROCESS RESEARCH & DEVELOPMENT | 1377 | 1% | 0% | 12 |
10 | JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 1312 | 1% | 0% | 14 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | 4 ANILINOQUINAZOLINE | 493625 | 2% | 73% | 22 | Search 4+ANILINOQUINAZOLINE | Search 4+ANILINOQUINAZOLINE |
2 | ANILINOQUINAZOLINE | 344212 | 1% | 75% | 15 | Search ANILINOQUINAZOLINE | Search ANILINOQUINAZOLINE |
3 | COMBI MOLECULE | 314712 | 1% | 86% | 12 | Search COMBI+MOLECULE | Search COMBI+MOLECULE |
4 | EGFR TK INHIBITORS | 225304 | 1% | 82% | 9 | Search EGFR+TK+INHIBITORS | Search EGFR+TK+INHIBITORS |
5 | QUINAZOLINE | 190555 | 6% | 9% | 66 | Search QUINAZOLINE | Search QUINAZOLINE |
6 | TYRPHOSTIN | 169914 | 3% | 18% | 31 | Search TYRPHOSTIN | Search TYRPHOSTIN |
7 | CI 1033 | 145779 | 1% | 53% | 9 | Search CI+1033 | Search CI+1033 |
8 | EGFR | 119562 | 15% | 3% | 150 | Search EGFR | Search EGFR |
9 | EGFR INHIBITORS | 111889 | 3% | 12% | 30 | Search EGFR+INHIBITORS | Search EGFR+INHIBITORS |
10 | EKB 569 | 100131 | 1% | 55% | 6 | Search EKB+569 | Search EKB+569 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |
rank | cluster_id2 | link |
---|---|---|
1 | 37409 | ADAPHOSTIN//INOSTAMYCIN//MOL LEVEL INTER E MIRC |
2 | 19631 | DIMERIZATION ARM//MED HEMATOL ONCOL BIOL CHEM//MOL DRUG DISCOVERY |
3 | 147 | GEFITINIB//EGFR MUTATION//ERLOTINIB |
4 | 3258 | QUINAZOLINONE//QUINAZOLINE//43H QUINAZOLINONES |
5 | 17211 | CSK//CHK//CSK HOMOLOGOUS KINASE |
6 | 6250 | NIMOTUZUMAB//CETUXIMAB//EGFR |
7 | 29828 | REGORAFENIB//FRUQUINTINIB//N DESETHYL SUNITINIB |
8 | 10374 | SRC//SRC INHIBITORS//C SRC |
9 | 24532 | UNIT 173//EGF R AND VEGF R PHOSPHORYLATION//M1B PROSTATE CANCER |
10 | 7485 | VANDETANIB//RAMUCIRUMAB//CEDIRANIB |